TOMI Environmental Solutions Expands Footprint Across Canada
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) announced expansion across Canada on March 16, 2026, driven by multiple SteraMist iHP technology placements in leading hospital systems and Canada’s largest health research organization.
The company reported integrations in a special pathogens unit, deployments at a Nova Scotia trauma center and a research university, and increased Canadian distributor inventory to support direct-to-customer sales and ongoing competitive bids for the fiscal year.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
TOMZ was down 3.65% pre-news while peers showed mixed action: LIQT -6%, DEVS -12.99%, CLWT roughly flat, ZONE -2.87%, and CLIR up 2.66%. Momentum data flags both up- and down-moves (2 peers each), indicating broader sector dynamics rather than a purely isolated move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | European partnership | Positive | -2.8% | Named Total Clean Air preferred European partner for SteraMist iHP. |
| Feb 23 | Biocide approvals | Positive | +12.7% | Received GB and NI biocidal product authorizations for BIT and SteraMist. |
| Jan 20 | Cleanroom CES sale | Positive | +0.6% | Sold Custom Engineered System integrating SteraMist iHP in UK cleanrooms. |
| Jan 06 | University installation | Positive | -3.0% | Installed SteraMist Hybrid System at a private East Coast research university. |
| Dec 22 | Cell/gene therapy deal | Positive | +1.4% | Multi-stage SteraMist iHP implementation at a new pharma manufacturing site. |
Recent positive commercial and regulatory updates have produced mixed reactions, with three aligned positive moves and two instances where upbeat news coincided with next‑day declines.
Over the past several months, TOMI has reported a series of growth and regulatory milestones. These include biocidal product approvals in Great Britain and Northern Ireland on Feb 23, 2026, a UK Custom Engineered System sale on Jan 20, 2026, and multiple SteraMist deployments in research and cell and gene therapy facilities. Despite this steady stream of expansion news, price reactions have alternated between gains and pullbacks, framing today’s Canada footprint news as part of an ongoing global commercialization push.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-11-14 allows TOMI to offer up to $50,000,000 of various securities over time, with proceeds earmarked for general corporate purposes such as working capital, capital expenditures, debt repayment, investments, acquisitions, or potential repurchases and redemptions. No usage has been recorded yet, but the facility provides flexibility for future capital raises.
Market Pulse Summary
This announcement highlights TOMI’s continued commercialization of SteraMist iHP, adding deployments in Canada’s largest health research organization, trauma care, and academic research settings. It extends a recent series of international and sector-specific wins, including approvals and installations in Europe and specialized U.S. facilities. Investors may track how these placements translate into recurring service revenue, monitor progress toward resolving Nasdaq listing deficiencies, and consider the potential use of the $50,000,000 S-3 shelf for future financing.
Key Terms
biosafety medical
pathogen medical
AI-generated analysis. Not financial advice.
Strategic Growth Driven by SteraMist iHP Technology Placements in Premier Healthcare and Pathogen Research Facilities
FREDERICK, Md., March 16, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced expansion of its presence across Canada following a series of strategic wins from late 2025 into early 2026. These placements include integrations within Canada’s largest health research organization and leading hospital systems, reflecting adoption of SteraMist iHP in high-containment research and critical care environments.
In a milestone for TOMI’s presence in the region, Canada’s largest health research organization has integrated SteraMist technology into its special pathogens unit. This adoption marks a critical step in maintaining high-level biosafety standards for national health research. Additionally, TOMI’s iHP Corporate Service team recently executed several successful deployments at a prominent Nova Scotia trauma center and a research university. These projects highlight the technology’s ability to provide rapid-response solutions in critical clinical and academic research settings.
To support this growth, TOMI’s Canadian distribution partner has increased its equipment inventory to facilitate direct-to-customer sales across the provinces. This infrastructure investment aligns with a pipeline of competitive bids currently submitted by TOMI for potential purchases throughout the current fiscal year.
“Our continued expansion in Canada reflects a shift toward more advanced, automated decontamination solutions across regulated healthcare and research environments,” said Elissa J. (E.J.) Shane, Chief Operating Officer at TOMI Environmental Solutions. “By securing placements in both elite research laboratories and critical care hospitals, we are reinforcing SteraMist iHP decontamination technology as the gold standard for pathogen control while supporting our expansion in North America.”
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services serving the healthcare and research sectors and expansion into Canadian markets. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Zach Nevas
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
What Canadian facilities did TOMI (TOMZ) place SteraMist iHP into in March 2026?
How is TOMI supporting its Canada expansion for TOMZ sales in 2026?
Does TOMI (TOMZ) claim SteraMist iHP meets biosafety needs in Canada?
What strategic benefits did TOMI (TOMZ) cite for its Canadian wins in March 2026?
Are there additional TOMI (TOMZ) opportunities pending in Canada after March 16, 2026?
